Communiqués Takeda Pharmaceutical Company Limited London S.E.

Actions

0A87

US8740602052

Produits pharmaceutiques

Marché Fermé - London S.E. 16:43:50 24/09/2026			Après clôture 21:59:55
18,55 ^USD	-0,70%		17,88	-3,64%

30/09	Les actions asiatiques négociées aux États-Unis sous forme de certificats américains de dépôt progressent modestement mercredi	MT
30/09	Takeda annonce que son nouveau traitement contre le psoriasis a surpassé celui d’un concurrent dans une étude de phase 3	MT

Communiqués

30/09	Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill	BU
22/09	Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026	BU
18/09	Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems	BU
14/09	U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations	BU
10/09	Takeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plump	PU
09/09	New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life	BU
31/08	Takeda Receives U.S. FDA Approval of MIMRYLO, Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera	AQ
29/08	Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera	BU
24/08	Takeda Pharmaceutical : Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn)	PU
24/08	ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1	BU
06/08	U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1	BU
30/07	Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2026 q1 er en)	PU
30/07	Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track	BU
23/07	Takeda Pharmaceutical : ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1	PU
17/07	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	BU
16/07	Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30	PU
13/07	Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	BU
09/07	Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange	PU
08/07	Takeda Pharmaceutical : Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees	PU
24/06	Takeda Pharmaceutical : Integrated Report (AIR 2026 EN)	PU
24/06	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO	BU
15/06	New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1	BU
11/06	Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations	BU
09/06	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease	BU
09/06	Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan	PU